Boyds appoints Vice President of Regulatory Affairs
Global drug development consultancy Boyds has appointed a Vice President of Regulatory Affairs in response to growing demand for its specialist services and expertise.
With over 25 years’ experience in medicines development and regulatory affairs, Carmen Vieira joins Boyds to further strengthen its regulatory offering. Previously, Carmen was an independent regulatory science and strategy advisor, supporting the expedited development of medicines for start-ups, biotechs, and big pharma developers. Prior to this, she was Head of Regulatory Affairs & Non-Clinical at the Cell and Gene Therapy Catapult.
She has also worked in senior regulatory affairs roles at AVROBIO, Janssen, ViroPharma SPRL, Astellas Pharma Europe, and Teva Pharmaceuticals Europe.
Trained as a pharmacist with a PharmD from Lisbon University, Carmen also completed postgraduate studies in the regulation and evaluation of medicines and health products.
As Vice President of Regulatory Affairs at Boyds, Carmen will provide strategic and operational regulatory advice to clients to support the expedited development of their medicines and therapies. She will also lead regulatory agency interactions, and guide Boyds’ Regulatory Affairs team, overseeing the delivery of key projects.
Carmen says: “Having previously collaborated with Boyds and its talented cross-functional experts, I’m really excited to be joining the Regulatory team. Over the years, I’ve been committed to meaningful innovation – addressing high unmet medical needs and fostering regulatory frameworks development in the ATMP space, and shaping regulations, particularly in the African region. At Boyds, I’m looking forward to building on this expertise and experience to help our clients develop commercially viable medicines and technologies for the benefit of patients.”
Dr Katherine Bowen, Chief Regulatory Affairs Officer at Boyds, comments: “We are delighted to have Carmen on board. Carmen is a great addition to our Regulatory Team, bringing over two decades of global experience across pharmaceutical, biotech, and academic environments. Importantly, she shares our passion for harnessing regulatory science not just to meet requirements, but to accelerate access to meaningful therapies by bridging science, strategy and patient needs. Global demand for our regulatory services continues to rise and Carmen’s appointment will strengthen our offering even further, as we strive to bring more therapies to market.”
Boyds was established in 2005 by Professor Alan Boyd and provides specialist consultancy services to a global client base, supporting the development of new, cutting-edge medicines for patient benefit.
For more information, please visit: www.boydconsultants.com
